Integration of smoking cessation into standard treatment for patients receiving opioid agonist therapy who are smoking tobacco: protocol for a randomised controlled trial (ATLAS4LAR)

Abstract Background About 85% of patients receiving opioid agonist therapy (OAT) for opioid dependence are smoking tobacco. Although smoke-related pulmonary diseases are significant contributors to morbidity and mortality, few smoking cessation interventions are evaluated within this group, and few...

Full description

Bibliographic Details
Main Authors: Karl Trygve Druckrey-Fiskaaen, Einar Furulund, Jan Tore Daltveit, Jørn Henrik Vold, Torgeir Gilje Lid, Tesfaye Madebo, Lars Thore Fadnes, for the ATLAS4LAR Study Group
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Trials
Subjects:
Online Access:https://doi.org/10.1186/s13063-022-06560-x

Similar Items